Emboline, Inc., a Santa Cruz, Calif.-based medical device company focused on reducing stroke and other damage caused by embolic debris released during transcatheter heart procedures, closed its Series D funding of over $55m.
The round was led by new investors Matrix Capital Management and an undisclosed strategic investor, with participation from existing investors SV Tech, ShangBay Capital, and Global Assets Investment. In conjunction with the financing, Eric Xiao, Principal at Matrix Capital Management along with a representative for the strategic investor have joined the Emboline Board of Directors.
The company intends to use the funds for a planned US-based pivotal trial for FDA approval as well as investigational studies for new indications, and manufacturing and commercial operations for the Emboliner.
Founded by Amir Belson, MD, and led by Scott Russell, President & CEO, Emboline is a medical technology company that has developed the Emboliner™ total embolic protection catheter, an embolic protection device designed to provide total embolic protection by capturing and removing all debris from transcatheter procedures that would otherwise travel to the brain, kidneys and other critical organs, and reducing the incidence of stroke, cerebral ischemia, cognitive decline and other adverse outcomes associated with procedure-related emboli.
The Emboliner™ is not yet commercially available and is intended for investigational use only.